Publications

Publications

Tumor vascular responses to antivascular and antiangiogenic strategies: looking for suitable models

By:
Contributors: Jihane Mriouah, PhD
Trends Biotechnol. 2012 Dec;30(12):649-58. doi: 10.1016/j.tibtech.2012.08.006. Epub 2012 Sep 26.

Abstract

Antiangiogenic and vascular disrupting agents are in the current cancer therapeutic armamentarium. A better understanding of the intricate mechanisms ruling neovessel survival within tumors during or after treatment is needed. Refinement of imaging and a growing knowledge of molecular biology of tumor vascularization provide new insights. It is necessary to define suitable methods for monitoring tumor response and appropriate tools to analyze data. This review compares most commonly used preclinical models, considering their recent improvements, and describes promising new approaches such as microfluidics, real-time electrical impedance based technique and noninvasive imaging techniques. The advantages and limitations of the in vitro, ex vivo and in vivo models are discussed. This review also provides a critical summary of emerging approaches using mathematical modeling.

 PubMed

Download PDF

Nanostics is pleased to announce the launch of clinical validation study

EDMONTON, June 4, 2019 /CNW/ – Nanostics Inc. is pleased to Announce the start of its key Clinical validation study. APCaRI is managing the study and recruitment has begun at Calgary’s Prostate Cancer Centre (PCC) and Edmonton’s Northern Alberta Urology Centre (NAUC). Recruitment of men from the Yukon Territories will follow.
The study will be conducted in partnership with DynaLIFE Medical Labs with co-principal investigators Dr. Eric Hyndman (PCC) and Dr. Adrian Fairey’s (NAUC).
Nanostics recognizes and is very grateful for the funding and support we received from the Bird Dogs from the beginning of this research and development journey. Nanostics also thanks funders for the clinical study including the Motorcycle Ride for Dad, Alberta Cancer Foundation, Alberta Innovates-ASBIRI program and the University Hospital Foundation Kaye Fund.

- Unknown